MNOVNasdaqPharmaceutical PreparationsUS GAAP · USD

MediciNova, Inc

MedicNova Inc. is a U.S.-based biopharmaceutical company focused on developing novel therapeutics for serious diseases with unmet medical needs. Its lead programs center on MN-166 (ibudilast) for neurological and inflammatory disorders and MN-001 (tipelukast) for fibrotic and metabolic diseases, with commercialization expected to rely on partners rather than an internal sales force.

Kysy yhtiöstä
Liikevaihto0,4milj. USD
−59,0 %v/v
Liikevoitto (EBIT)−13,3milj. USD
−4,8 %v/v
EBIT-marginaali−3 242,5%
−1 974,9 %-yks.v/v
Nettotulos−12,0milj. USD
−8,6 %v/v
Vapaa kassavirta−9,8milj. USD
+7,8 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−15−10−505milj. USD2020: EBIT −14 milj. USD20202021: 4,0 milj. USD2021: EBIT −10 milj. USD20212022: 4,0 milj. USD2022: EBIT −15 milj. USD20222023: 1,0 milj. USD2023: EBIT −9,9 milj. USD20232024: 1,0 milj. USD2024: EBIT −13 milj. USD20242025: 0,41 milj. USD2025: EBIT −13 milj. USD20250,41−13
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: MediciNova, Inc

Liiketoiminta

Osuus liikevaihdosta
MN-166 (ibudilast)55 %

Clinical-stage program targeting neurological and other disorders including MS, ALS, neuropathy, DCM, glioblastoma and ARDS prevention.

MN-001 (tipelukast)25 %

Clinical-stage program focused on fibrotic and metabolic disorders such as NAFLD and hypertriglyceridemia.

Research collaboration services5 %

Limited revenue from services performed under the Mayo Foundation agreement.

Intellectual property and licensing15 %

Patent portfolio and license agreements supporting current and future product candidates.

Asiakkaat

MedicNova does not currently sell approved pharmaceuticals at scale, so its direct customers are mainly research collaborators, clinical partners, and future licensing or commercialization partners. The company’s eventual end customers would be physicians, hospitals, and patients in specialty disease areas, but today value is created through clinical development and partner-enabled commercialization. Its current service revenue comes from a research agreement with Mayo Foundation, while product development is aimed at large unmet-need markets that would require reimbursement and formulary access.

Clinical research collaborators

Hospitals, academic centers and research groups that help run trials and generate data for MN-166 and MN-001.

Strategic licensing/commercialization partners

Pharmaceutical partners expected to help commercialize approved products outside the company’s small internal footprint.

Future prescribers and treatment centers

Neurologists, specialists and hospitals that would use approved therapies if the programs succeed.

Payers and reimbursement systems

Third-party payers and formularies that determine access and pricing for any approved drug.

Strategia

The company’s strategy is to concentrate resources on a small number of clinical programs with the highest unmet-need potential, especially MN-166 and MN-001. It is also building evidence through external collaborations, while relying on partners for manufacturing and future commercialization to keep the operating model asset-light.

Advance MN-166 clinical programsLyhyt aikaväli

MN-166 is the core asset and spans multiple neurological indications with potential partnering value.

Develop MN-001 in metabolic and fibrotic diseaseKeskipitkä aikaväli

MN-001 broadens the pipeline into liver and lipid-related disorders and diversifies clinical risk.

Use external partners for manufacturing and commercializationLyhyt aikaväli

The company lacks internal sales and manufacturing scale, so partners are essential to reach market.

Preserve capital while funding trialsLyhyt aikaväli

As a loss-making biotech, cash runway and disciplined spend determine how long programs can advance.

Maantiede

MedicNova is headquartered in the United States and states that its commercial focus is the U.S. market. Its development work is international in scope, with clinical and intellectual-property links in the U.K., Japan and other foreign markets, while manufacturing is outsourced to third parties rather than concentrated in company-owned plants. Geography matters because reimbursement, regulatory approval and partner access differ materially across the U.S. and international markets.

Riskit

MedicNova is exposed to the classic risks of a clinical-stage biotech: trial failure, regulatory delay, and dependence on third parties for manufacturing, data generation and eventual commercialization. It also faces financing and reimbursement risk because it has no approved product base, limited revenue, and must eventually secure payer access and partner support to monetize its pipeline.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Clinical development failure1Dependence on third-party manufacturers2Lack of commercialization infrastructure3Reimbursement and pricing pressure4Competition from larger pharma and biotech firms5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Clinical development failureVaikutus: KriittinenTodennäköisyys: Kohtalainen

    The company’s value depends on proving safety and efficacy in ongoing trials for MN-166 and MN-001.

    Kohdistuu: MN-166 and MN-001 programs

  2. Dependence on third-party manufacturersVaikutus: KorkeaTodennäköisyys: Kohtalainen

    API and finished product are outsourced, reducing control over quality, timing and scale-up.

    Kohdistuu: Clinical and future commercial supply

  3. Lack of commercialization infrastructureVaikutus: KorkeaTodennäköisyys: Kohtalainen

    The company has no internal sales and marketing capability and must rely on partners or build one later.

    Kohdistuu: Post-approval launch execution

  4. Reimbursement and pricing pressureVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Even if approved, formulary access and payer controls can restrict adoption and pricing.

    Kohdistuu: U.S. and international markets

  5. Competition from larger pharma and biotech firmsVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Competitors may reach market sooner or develop superior therapies for the same diseases.

    KohdistuuNeurologyFibrosisMetabolic disease markets
Kysy Clarifolta: MediciNova, Inc

Kirjanpito

Harkinnanvaraiset erät
Clinical trial accruals

Management must estimate costs for external service providers and trial-related obligations, which affects R&D expense and liabilities.

Vaikutus: Can shift expense recognition between periods

External development expense timing

MN-166 and MN-001 trial costs are recognized as incurred and can vary with study activity.

Vaikutus: Creates quarter-to-quarter volatility in operating loss

Service revenue recognition under Mayo agreement

Revenue is recognized as principal services are performed, so timing of patient enrollment and service delivery matters.

Vaikutus: Small but visible revenue line

Goodwill and indefinite-lived intangible impairment

Management performs qualitative impairment testing and adverse market or stock-price changes could trigger charges.

Vaikutus: Could create material non-cash write-downs

Stock-based compensation

Equity awards are a meaningful operating cost for a small biotech with limited cash resources.

Vaikutus: Affects G&A and reported loss

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Reviva Pharmaceuticals Holdings, Inc.

RVPH · Pharmaceutical Preparations

Teva Pharmaceutical Industries Limited

TEVA · Pharmaceutical Preparations

Relmada Therapeutics, Inc

RLMD · Pharmaceutical Preparations

Innoviva, Inc.

INVA · Pharmaceutical Preparations

Monopar Therapeutics

MNPR · Pharmaceutical Preparations

Novo Nordisk A/S

NVO · Pharmaceutical Preparations

Päivitetty: 24.9.2026